AUS
NZ
UK
CA
USA
IND
_08_26_2025_07_05_15_887419.jpg)
Highlights
- Imugene (IMU) advancing next-generation CAR T therapies
- Focus on accessibility through allogeneic “off-the-shelf” platforms
- Expansion into solid tumour treatments underway
Chimeric Antigen Receptor T-cell (CAR T) therapies have been one of the biggest breakthroughs in oncology, particularly for blood cancers where conventional treatment options often struggle. However, despite remarkable outcomes, challenges remain around manufacturing, cost, and scalability. As the biotech sector evolves, companies within and beyond ASX 200 companies are pushing to make this technology more accessible.
Imugene’s Allogeneic CAR T Program
Australian biotech Imugene (ASX:IMU) is at the forefront of this transformation. Its lead program, azer-cel, is designed as an allogeneic or “off-the-shelf” CAR T therapy. Unlike traditional autologous methods that require engineering a patient’s own cells, this approach uses healthy donor cells, which are engineered and stored for broader patient use. The concept aims to overcome delays and expand access to treatment.
The program has drawn regulatory recognition and is being tested in patients with aggressive blood cancers, including those who have limited options after previous therapies. Imugene is also preparing for discussions with the US Food and Drug Administration to progress a pivotal trial, a step that could accelerate its path toward regulatory approval.
Expanding Into Solid Tumours
While blood cancers have been the main focus of CAR T to date, Imugene is also tackling the more difficult challenge of solid tumours. Its onCARlytics platform introduces a novel strategy by using an engineered virus to mark tumours with CD19, enabling CAR T cells to recognise and attack them. This is being evaluated in clinical trials for advanced solid cancers, with different methods of delivery under study.
If successful, this could expand CAR T therapy into a much larger range of cancers and potentially reshape future treatment pathways.
Wider Industry Momentum
Globally, momentum in the CAR T field continues to grow. Large pharmaceutical companies such as Gilead Sciences (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) are reinforcing their positions through acquisitions and increased outreach, reflecting the growing role of CAR T in mainstream care. Their moves highlight the competitive environment in which Imugene operates, with both established leaders and emerging innovators seeking to shape the next generation of therapies.
Looking Ahead
The next phase for Imugene will involve further clinical data readouts, trial expansions into rare cancers, and advancing discussions with regulators. Success with both its allogeneic CAR T program and onCARlytics platform would place the company at the centre of an evolving oncology landscape where accessibility and scalability are set to define the future of treatment.
